Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other financing activities (2024 - 2025)

Allogene Therapeutics' Other financing activities history spans 2 years, with the latest figure at $3.6 million for Q2 2025.

  • For Q2 2025, Other financing activities rose 56.05% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $6.9 million, up 202.98%, while the annual FY2024 figure was $2.3 million, N/A changed from the prior year.
  • Other financing activities for Q2 2025 was $3.6 million at Allogene Therapeutics, up from $3.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $3.6 million in Q2 2025 and bottomed at $2.3 million in Q2 2024.